METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MUCOSAL INFLAMMATORY DISEASES
The mucosa is an integrated network of tissues, cells and effector molecules that protect the host from environmental insults and infections. Dysregulation of immunity at mucosal surfaces is thought to lead to mucosal inflammatory diseases such as those affecting the gastrointestinal system (Crohn's disease, ulcerative colitis and irritable bowel syndrome) and respiratory system (asthma, allergy and chronic obstructive pulmonary disorder). Anterior Gradient 2 (AGR2) is a dimeric Protein Disulfide Isomerase (PDI) family member involved in the regulation of protein quality control in the Endoplasmic Reticulum (ER). Its deletion in the mouse intestine increases tissue inflammation and promotes the development of inflammatory bowel disease (IBD). Now the inventors demonstrate that modulation of AGR2 dimer formation yields pro-inflammatory phenotypes notably though the secretion of AGR2 (eAGR2) that promotes monocyte attraction. The inventors show that in IBD and specifically in Crohn's disease, the levels of AGR2 dimerization modulators are selectively deregulated, and this correlates with severity of disease. The inventors thus demonstrate that AGR2 represent systemic alarm signals for pro-inflammatory responses in mucosa. Accordingly, the present invention relates to a method of treating a mucosal inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent which neutralizes the pro-inflammatory activity of eAGR2.
1 . A method of treating a mucosal inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent which neutralizes the pro-inflammatory activity of eAGR2.
2 . The method of claim 1 wherein the subject suffers from an inflammatory bowel disease (IBD).
3 . The method of claim 2 wherein the IBD is selected from the group consisting of Crohn's disease, ulcerative colitis and irritable bowel syndrome
4 . The method of claim 1 wherein the subject suffers from a mucosal inflammatory disease that affects the respiratory system.
5 . The method of claim 4 wherein the subject suffers from asthma or chronic obstructive pulmonary disorder.
6 . The method of claim 1 wherein the agent is an antibody specific for eAGR2.
7 . The method of claim 8 wherein the antibody binds to an epitope comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 in the amino acid sequence as set forth in SEQ ID NO:2 (PLMIIHHLDECPHSQALKKVFA).
8 . The method of claim 7 wherein the antibody binds to an epitope as set forth in SEQ ID NO:2.
9 . The method of claim 7 wherein the antibody comprises a heavy chain comprising at least one or at least two of the following CDRs:
H-CDR1:
(SEQ ID NO: 3)
DYNMD
H-CDR2:
(SEQ ID NO: 4)
DINPNYDTTSYNQKFQG
H-CDR3:
(SEQ ID NO: 5)
SMMGYGSPMDY
10 . The method of claim 7 wherein the antibody comprises a light chain comprising at least one or at least two of the following CDRs:
L-CDR1:
(SEQ ID NO: 6)
RASKSVSTSGYSYMH
L-CDR2:
(SEQ ID NO: 7)
LASNLES
L-CDR3:
(SEQ ID NO: 8)
QHIRELPRT
11 . The method of claim 7 wherein the antibody comprises a heavy chain comprising at least one of the following CDR i) the VH-CDR1 as set forth in SEQ ID NO:3 (DYNMD), ii) the VH-CDR2 as set forth in SEQ ID NO:4 (DINPNYDTTSYNQKFQG) and iii) the VH-CDR3 as set forth in SEQ ID NO:5 (SMMGYGSPMDY) and/or a light chain comprising at least one of the following CDR: i) the VL-CDR1 as set forth in SEQ ID NO:6 (RASKSVSTSGYSYMH), ii) the VL-CDR2 as set forth in SEQ ID NO:7 (LASNLES) and iii) the VL-CDR3 as set forth in SEQ ID NO:8 (QHIRELPRT).
12 . The method of claim 7 wherein the antibody comprises a heavy chain comprising the following CDR: i) the VH-CDR1 as set forth in SEQ ID NO:3 (DYNMD), ii) the VH-CDR2 as set forth in SEQ ID NO:4 (DINPNYDTTSYNQKFQG) and iii) the VH-CDR3 as set forth in SEQ ID NO:5 (SMMGYGSPMDY) and a light chain comprising the following CDR: i) the VL-CDR1 as set forth in SEQ ID NO:6 (RASKSVSTSGYSYMH), ii) the VL-CDR2 as set forth in SEQ ID NO:7 (LASNLES) and iii) the VL-CDR3 as set forth in SEQ ID NO:8 (QHIRELPRT).
13 . The method of claim 7 wherein the antibody comprises the heavy chain as set forth in SEQ ID NO: 9.
14 . The method of claim 7 wherein the antibody comprises a heavy chain as set forth in SEQ ID NO:9 mutated by four substitutions at positions 65, 67, 68 and 70, wherein said substitutions are characterized in that:
lysine (K) at position 65 is changed to glutamine (Q),
lysine (K) at position 67 is changed to arginine (R),
alanine (A) at position 68 is changed to valine (V), and
leucine (L) at position 70 is changed to methionine (M), and
wherein the numbers of the positions correspond to the Kabat numbering system.
15 . The method of claim 7 wherein the antibody comprises the heavy chain as set forth in SEQ ID NO: 10.
16 . The method of claim 8 wherein the antibody binds to an epitope comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 in the amino acid sequence as set forth in SEQ ID NO:11
(IHHLDECPHSQALKKVFAENKEIQKLAEQ).
17 . The method of claim 16 wherein the antibody binds to an epitope as set forth in SEQ ID NO:11.
18 . The method of claim 16 wherein the antibody comprises a heavy chain comprising at least one or at least two of the following CDRs:
H-CDR1:
(SEQ ID NO: 12)
NYGMN
H-CDR2:
(SEQ ID NO: 13)
WINTDTGKPTYTEEFKG
H-CDR3:
(SEQ ID NO: 14)
VTADSMDY
19 . The method of claim 16 wherein the antibody comprises a light chain comprising at least one or at least two of the following CDRs:
L-CDR1:
(SEQ ID NO: 15)
RSSQSLVHSNGN
L-CDR2:
(SEQ ID NO: 16)
IYLH
L-CDR3:
(SEQ ID NO: 17)
SQSTHVPLT
20 . The method of claim 16 wherein the antibody comprises a heavy chain comprising at least one of the following CDR i) the VH-CDR1 as set forth in SEQ ID NO:12 (NYGMN), ii) the VH-CDR2 as set forth in SEQ ID NO:13 (WINTDTGKPTYTEEFKG) and iii) the VH-CDR3 as set forth in SEQ ID NO:14 (VTADSMDY) and/or a light chain comprising at least one of the following CDR: i) the VL-CDR1 as set forth in SEQ ID NO:15 (RSSQSLVHSNGN), ii) the VL-CDR2 as set forth in SEQ ID NO:16 (IYLH) and iii) the VL-CDR3 as set forth in SEQ ID NO:17 (SQSTHVPLT).
21 . The method of claim 16 wherein the antibody comprises a heavy chain comprising the following CDR: i) the VH-CDR1 as set forth in SEQ ID NO:12 (NYGMN), ii) the VH-CDR2 as set forth in SEQ ID NO:13 (WINTDTGKPTYTEEFKG) and iii) the VH-CDR3 as set forth in SEQ ID NO:14 (VTADSMDY) and a light chain comprising the following CDR: i) the VL-CDR1 as set forth in SEQ ID NO:15 (RSSQSLVHSNGN), ii) the VL-CDR2 as set forth in SEQ ID NO:16 (IYLH) and iii) the VL-CDR3 as set forth in SEQ ID NO:17 (SQSTHVPLT).
22 . The method of claim 8 wherein the antibody cross-competes for binding to AGR2 with the antibody comprising a heavy chain comprising the following CDR: i) the VH-CDR1 as set forth in SEQ ID NO:3 (DYNMD), ii) the VH-CDR2 as set forth in SEQ ID NO:4 (DINPNYDTTSYNQKFQG) and iii) the VH-CDR3 as set forth in SEQ ID NO:5 (SMMGYGSPMDY) and a light chain comprising the following CDR: i) the VL-CDR1 as set forth in SEQ ID NO:6 (RASKSVSTSGYSYMH), ii) the VL-CDR2 as set forth in SEQ ID NO:7 (LASNLES) and iii) the VL-CDR3 as set forth in SEQ ID NO:8 (QHIRELPRT).
23 . The method of claim 8 wherein the antibody cross-competes for binding to AGR2 with the antibody comprising a heavy chain comprising the following CDR: i) the VH-CDR1 as set forth in SEQ ID NO:12 (NYGMN), ii) the VH-CDR2 as set forth in SEQ ID NO:13 (WINTDTGKPTYTEEFKG) and iii) the VH-CDR3 as set forth in SEQ ID NO:14 (VTADSMDY) and a light chain comprising the following CDR: i) the VL-CDR1 as set forth in SEQ ID NO:15 (RSSQSLVHSNGN), ii) the VL-CDR2 as set forth in SEQ ID NO:16 (IYLH) and iii) the VL-CDR3 as set forth in SEQ ID NO:17 (SQSTHVPLT).